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microRNAs (miRNAs) are 21–23-nucleotide non-coding
RNAs. It has become more and more evident that this class of
small RNAs plays critical roles in the regulation of gene expres-
sion at the post-transcriptional level.MEF2A is amember of the
MEF2 (myogenic enhancer factor 2) family of transcription fac-
tors. Prior report showed that the 3-untranslated region (3-
UTR) of the Mef2A gene mediated its repression; however, the
molecular mechanism underlying this intriguing observation
was unknown.Here, we report thatMEF2A is repressed bymiR-
NAs. We identify miR-155 as one of the primary miRNAs that
significantly represses the expression of MEF2A. We show that
knockdown of the Mef2A gene by siRNA impairs myoblast dif-
ferentiation. Similarly, overexpression of miR-155 leads to the
repression of endogenousMEF2A expression and the inhibition
of myoblast differentiation. Most importantly, reintroduction
ofMEF2A inmiR-155 overexpressedmyoblasts was able to par-
tially rescue the miR-155-induced myoblast differentiation
defect. Our data therefore establish miR-155 as an important
regulator ofMEF2Aexpression anduncover its function inmus-
cle gene expression and myogenic differentiation.
Determination of themyogenic lineage and differentiation of
skeletal muscle cells are precisely orchestrated by the MyoD
family of basic helix-loop-helix proteins (1–4). TheMyoD fam-
ily of myogenic transcription factors also activates muscle gene
expression in concert with additional transcription cofactors
and modifiers. In particular, MyoD and members of the MEF2
family of transcription factors synergistically activate the myo-
genic program (5). A key advance in understanding activation
of myogenic gene expression was the recognition of functional
interactions betweenmyogenic regulatory transcription factors
and additional regulators that either alter accessibility of chro-
matin structure or post-transcriptionally regulate gene expres-
sion (6).
MicroRNAs (miRNAs)2 are a class of 22-nt non-coding
RNAs that regulate gene expression at the post-transcriptional
level (7). The involvement of miRNAs in muscle biology
recently has been reported. miRNAs regulate the expression of
transcription factors and signaling mediators important for
cardiac and skeletal muscle development and function (8–10).
Aberrant miRNA expression has been observed in muscle dis-
eases, including cardiac and skeletal muscle hypertrophy, heart
failure, and muscular dystrophy (11–13). We have previously
shown that the expression of muscle-specific miR-1 and miR-
133 is induced during skeletal muscle differentiation. We fur-
ther demonstrated that miR-1 and miR-133 play central regu-
latory roles in myoblast proliferation and differentiation (14).
Interestingly, miR-1 andmiR-133 are also important regulators
of cardiomyocyte differentiation and heart development (15,
16).
MEF2A, a member of theMEF2 (myocyte enhancer factor 2)
family of transcription factors, is highly expressed in cardiac
and skeletal muscle (17). Interestingly, an earlier study found
that the expression of theMef2A gene is post-transcriptionally
repressed by its 3-UTR (18). However, the “trans-factors” that
mediate such repression was unknown. In this study, we
hypothesized that the expression and function of MEF2A is
repressed by miRNAs post-transcriptionally. We found that
miR-155 represses MEF2A expression in skeletal muscle, play-
ing an important role in skeletal muscle myoblast
differentiation.
EXPERIMENTAL PROCEDURES
Plasmids and Reporter Genes—The mouse MEF2A-3-UTR
was PCR amplified from a cDNA pool derived from an embry-
onic day 15.5 mouse embryo and was ligated 3 to a CMV pro-
moter luciferase reporter (14). The MEF2A 3-UTR mutation
was introduced using theQuikChange kit from Stratagene. The
N-FLAG-MEF2A-UTR was ligated into a modified N-FLAG
vector (14). The mouse -globin 3-UTR (131 bp) was PCR-
amplified from a mouse cDNA pool and cloned into the pGL3-
luciferase vector. DNA sequences encoding the primary miR-
155 transcript were PCR-amplified from a mouse genomic
DNA template and ligated into a modified pcDNA3.1 vector.
Mutation ofmiR-155was introduced byQuikChange kit (Strat-
agene). All mutations were confirmed by DNA sequencing.
miR-155mimic oligonucleotides and negative control mimic
oligonucleotides were purchased from Dharmacon.
Ad-siMEF2A and control virus were described previously
(19). Ad-MEF2A and control virus were gifts of Dr. Francisco
Naya (Boston University).
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Cell Culture, Transfection, and Muscle Differentiation
Assays—Transfection of 293T, Cos7, and C2C12 myoblasts
was performed as described previously (14, 20). Transient
transfection for luciferase reporter assays, unless otherwise
indicated, used 100 ng of reporter plasmid and 100 ng of each
activator ormiRNAplasmid. The total amount ofDNAperwell
was kept constant by adding the corresponding amount of
expression vector without a cDNA insert. CMV-LacZ or CMV-
GFP was included as an internal control for variations in trans-
fection efficiency. All of the transfection experiments were
repeated at least twice in duplicate or triplicate.
C2C12 myoblast cells were cultured and myogenic differen-
tiationwas induced as described (20)withminormodifications.
Briefly, cells were maintained in DMEM with 10% FBS. We
plated cells at 50–60% confluence and performed the trans-
fection the following day when they reached 90–100% con-
fluence. We collected cells on the same day of transfection (
6 h after transfection) and defined it as day 0 (G0). Cells were
switched to medium containing 2% horse serum to induce dif-
ferentiation, and samples were collected at the indicated dates.
Myogenesis was monitored by staining cells with myogenic
markers. Cells contain two or more nuclei are viewed as
myotubes.
siRNA Knockdown—C2C12 myoblasts cultured in growth
medium were infected by adenoviral siMEF2A or control virus
(19). 24 h later, culture was harvested as a G0 sample or viral
infected growth medium was exchanged by differentiation
medium and harvested at the indicated dates.
Immunoblotting and Immunostaining—Immunoblotting
(Western blot) was performed as described (21) using antibod-
ies against myogenin, MHC (Santa Cruz Biotechnology),
MEF2A (a gift of Dr. John McDermott, York University) and
-tubulin (Sigma). Immunostaining was performed as
described (14, 22). Briefly, cells cultured in plates were fixed in
4% paraformaldehyde for 10 min, washed with PBS and 0.1%
Nonidet P-40, blocked with 5% goat serum in PBS and 0.1%
Nonidet P-40 for 1 h at room temperature, incubated with pri-
mary antibodies overnight at 4 °C. After washing, cells were
incubated with secondary antibodies for 1 h at room tempera-
ture and counterstained with DAPI.
All images were acquired at room temperature from cell cul-
ture plates by a camera (ORCA-R2, Hamamatsu) mounted on
an invertedmicroscope (TE2000-U,Nikon). Digital fluorescent
images were captured at room temperature with a 10 (Plan
Fluor, air, numerical aperture, 0.30), 20 (Plan Fluor, air,
numerical aperture, 0.45), or 40 (Plan Fluor, air, numerical
aperture, 0.60) objective lens using the least possible exposure
tominimize bleaching. The imageswere processed using SPOT
software (version 3.5.4 for MacOS; Diagnostic Instruments)
andwere scaled down and cropped in Photoshop (AdobeAcro-
bat) to prepare the final figures. The myofiber surface area was
measured by Image J.
qRT-PCR—Total RNA was isolated with TRIzol reagent
(Invitrogen). After extraction andpurification, 1g of RNAwas
used as template for reverse transcription with random hex-
amer primers (Invitrogen). All PCR products span intron
region of the genes. Signal was detected by the 7500 Real-time
PCR System with SYBR green qRT-PCR master mix (Applied
Biosystems). Data were normalized by the GAPDH signal.
RESULTS
3-UTR of Mef2A Gene Mediates Its Post-transcriptional
Repression—In a prior report, it was shown that the 3-UTR of
the Mef2A transcript functioned as a “cis” element to mediate
repression of its expression (18). We cloned the full-length (nt
1834–2898) 3-UTR of the mouse Mef2A transcript and
inserted it downstream of a luciferase reporter. When the
reporter was transfected into 293T cells, luciferase activity was
significantly repressed when compared with a control con-
struct (Fig. 1A). Similarly, when theMef2A 3-UTR full-length
construct was transfected into Cos7 cells or C2C12 myoblasts,
luciferase activity was repressed (data not shown). When dele-
tion mutagenesis was applied to define regions of the 3-UTR
with the ability to mediate repression of the reporter gene, the
region from nt 2251–2679 was able to potently repress lucifer-
ase reporter activity (Fig. 1A), consistent with a previous report
(18). Further deletion analysis indicated that both the nt 2251–
2500 andnt 2500–2679 fragmentswere also able tomediate the
repression of the luciferase reporter gene (Fig. 1A). We
included a control reporter in which the 3-UTR of the mouse
-globin gene was clone downstream of the luciferase reporter
gene. We found that this reporter was slightly repressed when
transfected into the 293T cells, consistent with a prior report
(Fig. 1A) (18). This is not surprising because the -globin-3-
UTR could be a target for miRNAs to mediate the repression.
Next, we transfected 293T cells with FLAG-tagged expres-
sion plasmids for MEF2A, with and without 3-UTR (MEF2A-
ORF3-UTR or MEF2A-ORF), and then monitored protein
expression. MEF2A with the 3-UTR (MEF2A-ORF3-UTR)
resulted in a much lower expression level of protein, consistent
with the notion that the 3-UTR mediates its repression (Fig.
1B).
3-UTR of Mef2A Gene Is Target Site of miRNAs—We
hypothesized that the 3-UTR-dependent repression of the
Mef2A gene is mediated bymiRNAs. The 3-UTR of the mouse
Mef2A transcript is 1054 nt in length.We performed a bioin-
formatics analysis to identify putativemiRNAbinding sites (23)
and found that multiple miRNAs are predicted to target the
Mef2A 3-UTR. Luciferase reporter assays determined that sev-
eral miRNAs, includingmiR-9, miR-17–92, miR-19a, miR-155,
and miR-296, repress the activity of the Mef2A 3-UTR (Fig.
1C).
The nt 2251–2679 region of the Mef2A 3-UTR was previ-
ously reported tomediate its repressionmost potently (18).We
next sought to determine which of the miRNAs predicted to
target this region of theMef2A 3-UTR sequence could lead to
repression of MEF2A expression. Luciferase reporter assay
using theMEF2A3-UTR(2251–2679) demonstrated thatmiR-
19a (and miR-155) was able to repress MEF2A (Fig. 1D).
Sequence alignment showed that miR-155 binds to theMef2A
3-UTR at nt 2534–2557 (Fig. 1E), which is within the region
previously shown tomediate the repression ofMEF2A. Indeed,
miR-155 potently represses the MEF2A-3-UTR luciferase
reporters in a dose-dependent manner, but not that of the
-globin 3-UTR (Fig. 1F).When the seed sequence ofmiR-155
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FIGURE 1. The 3-UTR of the Mef2A gene mediates its repression. A, luciferase reporters containing the 3-UTRs of the mouse Mef2A gene were transfected
into the 293T cells, and luciferase activity was measured 48 h later. Results were presented as relative luciferase activity in which the control was assigned a
value of 1. The pGL-3-luciferase and the -globin-3-UTR-luciferase reporters were used to serve as controls. Data represent the mean  S.D. from at least three
independent experiments in triplicate. *, p  0.05. B, equal amount of FLAG-tagged MEF2A expression plasmids, which contains or does not contain its 3-UTR
were transfected into 293T cells. Protein expression level was measured by Western blot. -Tubulin was used as a loading control. C, a luciferase reporter
directed by the full-length MEF2A-3-UTR(1834 –2898) was co-transfected with indicated miRNA expression plasmids into the 293T cells, and luciferase activity
was measured 48 h later. Results were presented as relative luciferase activity in which the control was assigned a value of 1. The pGL-3-luciferase (control) and
the -globin-3-UTR-luciferase reporters were used to serve as controls. Data represent the mean  S.D. from at least three independent experiments in
duplicate. *, p  0.05. D, a luciferase reporter directed by a short MEF2A-3-UTR(2251–2679) was co-transfected with indicated miRNA expression plasmids into
the 293T cells, and luciferase activity was measured 48 h later. Results were presented as relative luciferase activity in which the control was assigned a value
of 1. The pGL-3-luciferase and the -globin-3-UTR-luciferase reporters were used to serve as controls. Data represent the mean  S.D. from at least three
independent experiments in duplicate. *, p  0.05. E, schematic diagram of the mouse Mef2A 3-UTR and the sequence alignment with miR-155. F, luciferase
reporters containing the 3-UTRs of the mouse Mef2A gene (full-length nt 1834 –2898 or the short form nt 2251–2679) were co-transfected with increasing
amount of miR-155 or a mutant miR-155 (miR-155-mut) into the 293T cells, and luciferase activity was measured 48 h later. Results were presented as relative
luciferase activity in which the control was assigned a value of 1. The -globin-3-UTR-luciferase reporter was used to serve as controls. Data represent the mean
 S.D. from at least three independent experiments in triplicate. *, p  0.05. G, FLAG-tagged MEF2A expression plasmids, which contain its 3-UTR, were
co-transfected with miR-155 or a mutant miR-155 into 293T cells. Protein expression level was measured by Western blot using an anti-FLAG antibody.
-Tubulin was used as a loading control.
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FIGURE 2. Knockdown of MEF2A impairs myoblast differentiation. A, quantitative real-time PCR measurement of Mef2A transcript expression during C2C12
myoblast differentiation at indicated dates. The result was presented as relative expression level in which the control was assigned a value of 1. Data represent
the mean  S.D. from at least three independent experiments. *, p  0.05. G0, growth medium day 0; D1, differentiation medium day 1; D3, differentiation
medium day 3. B, quantitative measurement of MEF2A protein expression during C2C12 myoblast differentiation at indicated dates. Results from Western blots
were quantified by densitometry measurement and presented as relative expression level in which the control was assigned a value of 1. Data represent the
mean  S.D. from at least three independent experiments. *, p  0.05. C, quantitative Taqman PCR measurement of mature miR-155 expression during C2C12
myoblast differentiation at indicated dates. Result was presented as relative expression level in which the control was assigned a value of 1. Data represent the
mean  S.D. from at least three independent experiments. *, p  0.05. D, immunohistology of C2C12 cells treated with either control or MEF2A-specific siRNAs.
Cells were induced to differentiate at different time courses (differentiation day 1 or day 3) and were stained with antibodies that recognize striate muscle MHC
(green) and myogenin (red). DAPI stains nuclei. DM1, differentiation medium day 1; DM3, differentiation medium day 3. E, quantitative analyses of cell numbers
of myoblast (MHC-positive, single nucleus) and myotubes (MHC-positive, three or more nuclei) in siMEF2A-treated C2C12 cells when compared with control
siRNA treatment. Data represent the mean  S.D. from at least three independent experiments. *, p  0.05. F, quantitative analyses of cell size of myoblast and
myotubes in siMEF2A-treated C2C12 cells when compared with control siRNA treatment. Left panel, distribution of myoblast and myotube size. Right panel,
average size of myoblast and myotube size. Data represent the mean  S.D. from at least three independent experiments. *, p  0.05. G, quantitative real-time
PCR analyses of gene expression in siMEF2A-treated C2C12 myoblasts and myotubes. Result was presented as relative expression level in which the control was
assigned a value of 1. Data represent the mean  S.D. from at least three independent experiments. *, p  0.05. H, Western blot analyses of protein expression
in siMEF2A-treated C2C12 myoblasts and myotubes, using antibodies recognize indicated proteins.
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was mutated, mutant miR-155 was unable to repress the
reporter, demonstrating the specificity of such repression (Fig.
1F). Consistentwith the results of the luciferase reporter assays,
miR-155, but not the miR-155 mutant, significantly represses
the expression level of theMEF2A protein whenmiR-155 and a
FLAG-tagged MEF2A expression plasmid containing its
3-UTRwere co-transfected into 293T cells (Fig. 1G). Together,
these experimental results indicate that miR-155 represses the
Mef2A gene via its 3-UTR.
miR-155 Represses Myoblast Differentiation by Repressing
MEF2A—The MEF2 family of transcription factors regulates
gene expression in both cardiac and skeletalmuscle (17). A gene
targeting study demonstrated that MEF2A knock-out mice die
post-natally with cardiovascular defects and cardiac failure
(24). However, the function of MEF2A in skeletal muscle was
not determined. We examined the expression of the Mef2A
transcript in C2C12 skeletal muscle myoblasts and found its
level was increased when C2C12 myoblasts were induced to
FIGURE 3. MEF2A is repressed by miR-155 via its 3-UTR. A, immunohistology of C2C12 cells treated with either control or miR-155. Cells were induced to
differentiate at indicated dates and were stained with antibodies that recognize striate muscle MHC (green) and myogenin (red). DAPI stains nuclei. DM1,
differentiation medium day 1; DM3, differentiation medium day 3. B, quantitative analyses of cell numbers of myoblast (MHC-positive, single nucleus) and
myotubes (MHC-positive, three or more nuclei) in miR-155 overexpressed C2C12 cells when compared with control miRNA treatment. Data represent the mean
 S.D. from at least three independent experiments. *, p  0.05. C, quantitative analyses of cell size of myoblast and myotubes in miR-155 overexpressed C2C12
cells when compared with control miRNA treatment. Left panel, distribution of myoblast and myotube size. Right panel, average size of myoblast and myotube
size. Data represent the mean  S.D. from at least three independent experiments. *, p  0.05. D, quantitative real-time PCR analyses of gene expression in
miR-155 overexpressed C2C12 myoblasts and myotubes. Result was presented as relative expression level in which the control was assigned a value of 1. Data
represent the mean  S.D. from at least three independent experiments. *, p  0.05. ACTA, skeletal muscle -actin; G0, growth medium day 0; D1, differentiation
medium day 1; D3, differentiation medium day 3. E, quantitative measurement of protein expression in miR-155 overexpressed C2C12 myoblasts, using
antibodies recognize indicated proteins. Results from Western blots were quantified by densitometry measurement and presented as relative expression level
in which the control was assigned a value of 1. Data represent the mean  S.D. from at least three independent experiments. *, p  0.05.
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differentiate into myotubes (Fig. 2A). Similarly, we observed a
significant increase in the expression of MEF2A protein during
C2C12 differentiation (Fig. 2B).We investigated the expression
of miR-155 in skeletal muscle using Taqman qRT-PCR. Inter-
estingly, the expression level of miR-155 is decreased in differ-
entiating myoblasts, which is inversely correlated with that of
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MEF2A (Fig. 2C). Note that the decrease ofmiR-155 expression
(a 50% decrease) and the increase of MEF2A protein levels
(a  2 fold increase) at Day 3 (D3) is not in a linear inverse
correlation, suggesting that additional miRNAs may also con-
tribute to the repression of MEF2A expression. Use of a miR-
155 sensor reporter in C2C12 myoblasts further confirmed the
above observation (supplemental Fig. S1).
We asked whether miR-155 mediated repression of MEF2A
expression has a functional consequence in skeletal muscle
cells. We first tested whether MEF2A is required for myoblast
differentiation in cultured C2C12 myoblast cells. Endogenous
MEF2A was dramatically knocked down by a MEF2A-specific
siRNA but not by a control siRNA. Transfectedmyoblasts were
then switched to differentiation medium to induce myogenic
differentiation.We found thatmyoblast differentiationwas sig-
nificantly impaired, as evidenced by a significant decrease in the
number and size of myotubes (Fig. 2D and supplemental Fig.
S2). Quantification of mononucleus myoblasts andmultinuclei
myotubes clearly demonstrated a marked decrease in myotube
formation in MEF2A knocked down cells (Fig. 2, E and F).
Molecular marker measurements confirmed that the tran-
scripts of myogenic differentiation markers, including myoge-
nin and skeletal muscle -actin, were all decreased in MEF2A
knocked down cells (Fig. 2G). Western blot analysis further
supported the notion of decreased myogenic differentiation in
MEF2A knocked downmyoblasts (Fig. 2H). These data suggest
that MEF2A is required for proper differentiation of C2C12
myoblasts. Conversely, adenovirus-based overexpression of
MEF2A in C2C12myoblasts enhancesmyoblast differentiation
(supplemental Fig. S3).
Next, we tested whether miR-155 is involved in the regula-
tion of myoblast differentiation. We transfected a miR-155
expression vector or synthetic miR-155 mimics into undiffer-
entiated C2C12 myoblasts. Overexpression of miR-155
repressed the expression level of endogenous MEF2A. As
expected, overexpression of miR-155 inhibited the differentia-
tion of myoblasts. Similar to what we observed in MEF2A
knockdownmyoblasts, but to a lesser extent, we found less and
smaller myotube formation in miR-155 overexpressed myo-
blasts when they were switched to differential medium to
induce differentiation (Fig. 3A and supplemental Fig. S4).
Quantitative measurement of the number and size of myoblast
and myotube demonstrated that miR-155 decreased the size
and number of myotubes (Fig. 3, B and C). Molecular marker
analyses, using both quantitative RT-PCR and Western blot,
confirm thatmiR-155 repressesmyoblast differentiation (Fig. 3,
D and E). In addition to miR-155, several other miRNAs also
repressed MEF2A-3-UTR-luc reporter (Fig. 1C). Among
them, miR-19a binding site was mapped to the region between
nt 2251–2679 of theMEF2A-3-UTR.We tested whether miR-
19a and miR-296 could also repress C2C12 myoblast differen-
tiation. Unlike that of miR-155, miR-19a and miR-296 did not
affect myoblast differentiation (supplemental Fig. S5).
Overexpression of MEF2A Partially Rescues miR-155-medi-
ated Myoblast Differentiation Defects—The above results indi-
cate that either knockdown of MEF2A or overexpression of
miR-155 leads to the inhibition of myoblast differentiation.
Given that miR-155 inhibits the expression of MEF2A post-
transcriptionally, we tested whether overexpression of MEF2A
could rescue, at least in part, miR-155-mediated C2C12 myo-
blast differentiation defects. An adenoviral expression vector
containing the Mef2A ORF without the 3-UTR was used to
overexpress the MEF2A protein. As shown in Fig. 4A, whereas
miR-155 repressed myoblast differentiation, overexpression of
MEF2A partially suppressed miR-155-mediated inhibition of
myogenic differentiation. Results from quantitative measure-
ment of myoblast and myotube size supported the view (Fig.
4B). qRT-PCR and Western blot analyses showed that the
expression of myogenic markers was partially rescued by over-
expression of MEF2A (Fig. 4, C and D).
DISCUSSION
In this study, we found that miR-155 represses the level of
transcription factorMEF2Aby binding to the 3-UTRofMef2A
mRNA. We showed that miR-155-mediated repression of
MEF2Aplays a role in the regulation ofmuscle gene expression.
Our findings therefore uncover a novel function for miR-155
and MEF2A in regulating the differentiation of skeletal muscle
myoblasts.
miRNAs are a class of novel regulators for gene expression,
and they have been demonstrated to be involved almost every
aspects of biology, from stem cells, cell proliferation, differen-
tiation, apoptosis to related diseases.We and others (14, 25–27)
demonstrated previously that miR-1, miR-133, miR-206, and
othermusclemiRNAs (myomiRs) regulate skeletal muscle pro-
liferation and terminal differentiation. Given the importance of
MEF2A in cardiac and skeletal muscle gene expression, it is
conceivable that the repression of MEF2A, either by
siRNA-dependent repression or miR-155-mediated inhibition,
impaired skeletal muscle myoblast differentiation. Indeed, our
data demonstrated that inhibition of MEF2A by miR-155
represses myogenic differentiation. Recently, we also found
that miR-1 represses MEF2A in cardiomyocytes (28).
Whereas our data clearly established a role for miR-155 in
repressing MEF2A expression and myogenic differentiation,
we are aware of the observation thatmiR-155-mediated repres-
sion of MEF2A only led to modest repression of myoblast dif-
ferentiation. Our observation is consistent with many prior
FIGURE 4. miR-155 inhibits myoblast differentiation which is suppresses by MEF2A. A, immunohistology of C2C12 cells treated with control, miR-155,
Ad-MEF2A, or both miR-155 and Ad-MEF2A. Cells were induced to differentiate at indicated dates and were stained with antibodies that recognize striate
muscle MHC (green) and myogenin (red). DAPI stains nuclei. GM1, growth medium day 1; DM1, differentiation medium day 1; DM3, differentiation medium day
3. B, quantitative analyses of cell size of MHC positive myoblast and myotubes in C2C12 cells treated with control, miR-155, MEF2A, or both miR-155 and MEF2A.
The distribution of myoblast and myotube size was presented as percentage. C, quantitative real-time PCR analyses of gene expression in C2C12 cells treated
with control, miR-155, MEF2A, or both miR-155 and MEF2A. Result was presented as relative expression level in which the control was assigned a value of 1.
Data represent the mean  S.D. from at least three independent experiments. *, p  0.05. G0, growth medium day 0; D1, differentiation medium day 1; D3,
differentiation medium day 3. D, Western blot analyses of protein expression levels in C2C12 cells treated with control (contl), miR-155, MEF2A, or both miR-155
and MEF2A. D2, differentiation medium day 2.
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reports and current view on howmost miRNAs work, in which
miRNAs are thought to modestly modulate target gene expres-
sion and tips the balance of the biological system (22, 29–32).
We noticed that additional cis-element presented in the
3-UTR of the Mef2A transcript could also mediate its repres-
sion, indicating that miR-155 is not the only miRNA that
represses the expression and inhibits the function ofMEF2A. In
fact, our results show that the 3-UTR of Mef2A mediates its
repression bymiR-17–92,miR-9, miR-19a, miR-296, and prob-
ably other miRNAs (Fig. 1C). Whether such repression medi-
atesMEF2A function in myogenesis remains to be determined.
miR-155 is derived from the non-protein-coding transcript
of the BIC locus (33). Recent studies have established miR-155
a critical player in the immunosystem. It also functions as an
oncogenic miRNA (34–37). In those studies, miR-155 was
demonstrated to repress the expression of different targets,
including SMAD2 (38), tumor protein 53-induced nuclear pro-
tein 1 (TP53INP1) (39), and Pu.1 (36). However, there was no
report regarding to the potential function of this miRNA in
cardiac and skeletalmuscle. Our current studies, using cultured
myoblast cell line in vitro, convincingly demonstrate the func-
tion ofmiR-155 inmyoblast differentiation. It will be important
for the future to determine whether the repression of MEF2A
by miR-155 contributes to skeletal muscle development and
function in vivo. It will also be interesting to investigatewhether
miR-155 and MEF2A participate in skeletal muscle degenera-
tion/regeneration process as well as degeneration-related
human muscular diseases, such as muscular dystrophy.
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